Trials / Terminated
TerminatedNCT00469963
Internal Radiation Therapy in Treating Patients With Primary Liver Cancer That Cannot Be Removed by Surgery
Clinical Trial of Sir Spheres® in Patients With Primary Hepatocellular Carcinoma
- Status
- Terminated
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Vanderbilt-Ingram Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
RATIONALE: Specialized internal radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. PURPOSE: This clinical trial is studying how well internal radiation therapy works in treating patients with primary liver cancer that cannot be removed by surgery.
Detailed description
OBJECTIVES: Primary * Determine tumor response to selective internal radiation therapy comprising yttrium Y 90 resin microspheres (Sir-Spheres®) in patients with unresectable primary hepatocellular carcinoma. Secondary * Determine the toxicity of this regimen in these patients. * Determine the health-related quality of life of patients receiving this regimen. * Determine the survival of patients receiving this regimen. OUTLINE: Patients undergo selective internal radiation therapy comprising yttrium Y 90 resin microspheres (Sir-Spheres®) via catheter directly into the hepatic artery on day 1. Health-related quality of life is assessed prior to initial treatment and then periodically thereafter. After completion of study treatment, patients are followed periodically for 12-24 months. PROJECTED ACCRUAL: A total of 35 patients will be accrued for this study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | quality-of-life assessment | quality-of-life assessment |
| RADIATION | yttrium Y 90 resin microspheres | radiation therapy |
Timeline
- Start date
- 2003-12-01
- Primary completion
- 2006-10-01
- Completion
- 2007-04-01
- First posted
- 2007-05-07
- Last updated
- 2012-09-03
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00469963. Inclusion in this directory is not an endorsement.